Address: Lage Mosten 33, 4822 NK, Noord-Brabant,Netherlands
As a global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009, UCB aspires to be the patient-centric global biopharmaceutical leader transforming the lives of people living with severe diseases.
By integrating biology (bio) and chemistry (pharma), we can gain much deeper insights into disease pathways, including the complexities of severe diseases, as well as producing more potent, cost-effective drugs.
The unique combination of expertise in large, antibody-based molecules and small, chemically-derived molecules places us in a strong position to realise this ambition. Cimzia®, our New Biological Entity (NBE), targeted at Crohn’s disease and rheumatoid arthritis, is one of the first fruits of this synergy of biology and chemistry.
Products and services
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Vimpat® (lacosamide): Epilepsy
Keppra® (levetiracetam): Epilepsy
Neupro® (rotigotine): Parkinson’s disease, Restless Legs Syndrome
Nootropil® (piracetam): Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII): Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol): Crohn’s disease, Rheumatoid arthritis
Xyzal® (levocetirizine): Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII): Respiratory disease